Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA01 - Multimodality Management of Advanced Lung Cancer

    • 08:15 - 09:15
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Multimodality of Advanced Lung Cancer
    • +

      MA01.06 - Effects of the Immunotherapy Era on Maintenance Outcomes in Advanced Nonsquamous NSCLC: Subgroup Analysis of ECOG 5508

      08:50 - 08:55  |  Presenter: Bharathi Muthusamy

      • Abstract

      Loading...

  • +

    OA01 - The Impact of COVID-19 on Patients with Lung Cancer

    • 08:15 - 09:15
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Management of Lung Cancer in the Era of COVID-19
    • +

      OA01.04 - Discussant

      08:45 - 08:55  |  Presenter: Suresh Ramalingam

      • Abstract

      No abstract available for this presentation

  • +

    OA03 - Novel Approaches to Cessation in Cancer Care

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Risk Reduction and Tobacco Control
    • +

      OA03.03 - Patient Factors Associated With Engagement of an Academic Institution Tobacco Cessation Referral Program

      09:50 - 10:00  |  Presenter: Sarah Westergaard

      • Abstract

      Loading...

  • +

    IS01 - Industry Symposium Sponsored by Mirati Therapeutics: Rapid Progress During a Pandemic: Emerging Therapeutic Options for NSCLC

    • 12:00 - 13:00
    • 9/08/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS01.02 - Recent Advances and Current Approaches to Address Unmet Needs in Advanced NSCLC

      12:05 - 12:20  |  Presenter: Suresh Ramalingam

      • Abstract

      No abstract available for this presentation

  • +

    FP01 - Early Stage/Localized Disease/Ablative Therapies

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Early Stage/Localized Disease/Ablative Therapies
    • +

      FP01.01 - The Association of Bevacizumab with a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505 in Completely Resected Stage IB-IIIA NSCLC

      00:00 - 00:00  |  Presenter: John Varlotto

      • Abstract

      Loading...

  • +

    FP07 - Mesothelioma, Thymoma and Other Thoracic Malignancies

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
    • +

      FP07.05 - DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

      00:00 - 00:00  |  Presenter: Anna Nowak

      • Abstract

      Loading...

  • +

    FP08 - Multimodality Management of Advanced Lung Cancer

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Multimodality of Advanced Lung Cancer
    • +

      FP08.01 - Lung Stereotactic Body Radiation Therapy for Treatment of Oligoprogressive and Oligorecurrent Metastatic Disease: A Multi-Center Analysis

      00:00 - 00:00  |  Presenter: Sibo Tian

      • Abstract

      Loading...

  • +

    FP09 - Novel Therapeutics and Targeted Therapies

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      FP09.01 - Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy

      00:00 - 00:00  |  Presenter: Pasi A. Janne

      • Abstract

      Loading...

    • +

      FP09.02 - Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort

      00:00 - 00:00  |  Presenter: Maria Rosario García Campelo

      • Abstract

      Loading...

  • +

    FP16 - Tumor Biology and Systems Biology: Basic and Translational Science

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Tumor Biology and Systems Biology: Basic and Translational Science
    • +

      FP16.03 - Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial

      00:00 - 00:00  |  Presenter: Myung-Ju Ahn

      • Abstract

      Loading...

  • +

    P50 - Novel Therapeutics and Targeted Therapies - EGFR Minor

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P50.05 - Natural History and Real-World Treatment Outcomes for NSCLC Patients with EGFR Exon 20 Insertion Mutation: An IASLC- ASCO CancerLinQ Study

      00:00 - 00:00  |  Presenter: Madhusmita Behera

      • Abstract

      Loading...